Initiation of Clozapine Treatment Community Patients

Size: px
Start display at page:

Download "Initiation of Clozapine Treatment Community Patients"

Transcription

1 Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A

2 Initiation of Clozapine Treatment for Patients in the Community CONTENTS 1.0 Introduction Appropriate Clients Preparation Program for Home Initiation Program for Day Care Initiation (includes partial hospitalisation and patients in crisis flats) Documentation and Support Tools Training and Audit 8 APPENDICES PAGE NUMBER 1. Clozapine Out-Patient Initiation Checklist Clozapine Initiation Prescription Chart 11/12 3. Titration and use of other Antipsychotics 13 Version 1.0 January

3 1. Introduction 1.1 Clozapine has been established as an effective therapy for treatmentresistant psychosis. It has been shown to have benefits in terms of quality of life and reduction of both positive and negative symptoms and it is cost-effective in the long term because of the reduction in hospital admissions. For suitable patients, community initiation of clozapine will improve their access to an effective treatment. It will allow patients to be treated in the environment most appropriate for them. It is also likely to result in a more effective use of in-patient beds. 1.2 Day care and home initiation should not be seen as separate entities. With some patients it may be more appropriate to use a combination of the two with patients attending day care on some days and being visited by a health care professional in their homes on others. 1.3 Abbreviated information contained in the following sections 2 5 are contained in the attached out patient initiation checklist (appendix 1) and out patient initiation daily planner (appendix 2). 2. Appropriate Clients 2.1 Patients should consent to clozapine treatment and blood tests and be aware of and agree to the necessity for an initial period of daily contact at home or daily attendance at an Acute Directorate Day Hospital. 2.3 A full history and clinical investigations should be performed to identify patients for whom home initiation is excluded (history of seizures, NMS) or where caution including slower titration should be exercised (diabetes or history of cardiac disease, harmful substance abuse, older persons, patients receiving potent sedatives or benzodiazepines). 2.4 Patients with a supportive family or carer network and home environment may be more suitable for home initiation. It will be preferable but not essential for a carer to stay with the patient overnight. 3. Preparation 3.1 The sector consultants would be responsible for making the initial decision to start Clozapine and to prepare the client for home initiation. Each case should be considered on an individual basis with individualized decision making and planning involving the patient and carers where possible. Patients, family members and carers should be provided with written information about clozapine. 3.2 Arrangements will be then made by the medical staff from their team to perform a physical examination as a normal workup for anti-psychotic Version 1.0 January

4 medication including base line weight, temperature, pulse and blood pressure (lying and standing). Further investigations may include ECG, blood glucose, according to clinical indications and judgment. 3.3 Psychiatric base line measurements wherever possible should be conducted in order to measure response. 3.4 Pharmacy should be informed about the decision to start Clozapine and the necessary forms completed. The Zaponex Treatment Access Service (ZTAS) requires the Patient Data form to be signed by the pharmacist before faxing it to them. 3.5 The Client should be registered with the Zaponex Treatment Access Service (ZTAS) before referral to the CR/HT team. A baseline full blood count (white cells, neutrophils and platelets) should be taken and the result written on the registration form. 3.6 Special consideration should be given to concomitant medications likely to involve possible drug interactions e.g. bone marrow suppressants, benzodiazepines, anti-cholinergics, anti-hypertensives, alcohol, MAOI s, CNS depressants, highly protein bound drugs, phenytoin, lithium. 3.7 The patient s GP should be informed of the initiation of clozapine (appendix 4 gives Zaponex abbreviated prescribing information) and an emergency contact number for the treating team. This is in the event of a patient seeking help from the GP for an adverse reaction. There is no expectation that the GP will be required to take on the prescribing of clozapine. 3.8 The patient must be provided with an emergency contact number for the treating team and out-of-hours services. 3.9 There should be a contingency plan in case the patient defaults from visits or becomes non-compliant. This contingency plan should address the issues of the management of relapse, haematological monitoring which continues for four weeks after cessation, and a plan for either restarting clozapine or alternative antipsychotic medication The mode of transfer from previous medication to clozapine needs to be planned according to severity of symptoms and risk of relapse. Complex out patient cross titration of antipsychotics should be avoided Routine blood samples will be taken on Tuesdays, with tablets being ready for collection Friday. Version 1.0 January

5 4. Program for home initiation 4.1 The CR/HT Consultant will assume responsibility for home initiation after the client has been prepared and referred to the service. A nurse co-ordinator will be appointed to coordinate the client s care whilst with the CR/HT team. After an initial assessment clients deemed suitable would be started on the program. Day 1 should be a Monday avoiding weeks with bank holidays. This will enable the first post initiation full blood count (taken on Tuesday) to be obtained and sent to the ZTAS central lab. It will also ensure maximum availability of staff and support services. The critical period, especially for clozapine naïve patients, will be the early days of treatment and associated with dose increases. Risks include sudden collapse, syncope, cardiac and respiratory complications. 4.2 The patient should be visited by a suitably trained healthcare professional every weekday, ideally for the first 2 weeks but as a minimum for 1 week. The actual length of attendance is subject to medical review. 4.3 Day 1 (Monday) A suitably trained healthcare professional must remain with the patient in his/her home for at least the first few hours after administering the clozapine dose; pulse, temperature and blood pressure (lying and standing) should be taken before giving the clozapine and every hour after initial dose for a few hours. (NB. Patient can attend day-care for this first day if this is more convenient, different healthcare professionals may stay with the patient in shifts throughout the day). Being physically present for long periods may not be necessary for patients with previous uneventful exposure to clozapine who are restarting after breaks in treatment. Lying and standing BP may not always be possible or indicated where the patient is sedated. NOTE: the start day must be within 9 days of the baseline blood test. 4.4 Day 2 (Tuesday) healthcare professional takes the patient s pulse, temperature and blood pressure (lying and standing). They then administer the clozapine dose and repeat the pulse, temperature and BP at 2 hours and then at 6 hours after dose. There is not a requirement to stay with the patient between observations. 4.5 The second blood test should be taken on day 2 (Tuesday) and posted to the ZTAS central laboratory to ensure that the result is available to allow dispensing of the medication to continue into the second week. The blood tests are then to be performed weekly thereafter on Tuesday until otherwise advised. 4.6 Day 3 onwards healthcare professional takes the patient s pulse, temperature and blood pressure. They then administer the Version 1.0 January

6 clozapine dose. They must return after 6 hours to repeat the pulse, temperature and BP and assess the patient. 4.7 Pulse, temperature and standing and lying BP should be performed at least twice a day by the healthcare professional. 4.8 Utilise flexible dosage titration some patients may require slow titration (appendix 3). 4.9 Do not increase the dose of clozapine at the weekend or on Bank Holidays Clozapine dose may be divided after one week depending on preference for type of dosing regimen and adverse reactions experienced A doctor should visit regularly and at a minimum once every week. The doctor should assess the patient in a similar way to that which would be carried out if the patient were an in-patient i.e. assessing the patient s progress, assessing any adverse reactions to clozapine, adjusting the titration rate, managing anti-psychotic medication crosstitration, reassuring the patient At regular intervals, psychiatric measurements should be performed and risk assessed in order to monitor progress After the completion of treatment the client should be handed back to his sector consultant with arrangements in place for further monitoring and follow up such as out patient appointments, clozapine clinic appointments, etc Any adverse event should be reported to the ZTAS as well as to the R.M.O and appropriate action should be taken that may include reducing/ stopping clozapine,hospitalisation etc. 5. Program for day care initiation (includes partial hospitalisation and patients in crisis flats) 5.1 Day 1 should be a Monday avoiding weeks with bank holidays. This will enable the first post initiation full blood count (day 2) to be obtained and sent to the ZTAS central lab. It will also ensure maximum availability of staff and support services. The critical period, especially for clozapine naïve patients, will be the early days of treatment and associated with dose increases. Risks include sudden collapse, syncope, cardiac and respiratory complications. 5.2 Patient to attend day-care every weekday ideally for the first 2 weeks but as a minimum for 1 week. Actual length of attendance is subject to Version 1.0 January

7 medical review. Patients must be accompanied home either by a carer / relative or a healthcare worker from day care. 5.3 Day 1 (Monday) patient attends day-care in the morning and receives clozapine dose. Pulse, BP (lying and standing) and temperature are taken before giving the clozapine and then at hourly intervals for 6 hours. Patient stays at day-care all day. Patient must be accompanied home either by a carer / relative or a healthcare worker on each day. Lying and standing BP may not always be possible or indicated where the patient is sedated Day 2 patient attends day-care in the morning and has pulse, temperature and BP performed before receiving clozapine dose. Pulse, temperature and BP should be recorded at 2 hours and then at 6 hours after dose. Patient stays at day-care all day The second blood test should be taken on day 2 (Tuesday) and posted to the ZTAS central laboratory to ensure that the result is available to allow dispensing of the medication to continue into the second week. The blood tests are then to be performed weekly thereafter on Tuesday until otherwise advised. 5.5 Day 3 patient attends day-care in the morning with pulse, temperature and BP being done on arrival before receiving clozapine dose and before going home. Although patient may be allowed to leave the unit during the day, they should return for their final pulse, temperature and BP readings 6 hours after the dose of clozapine was given. 5.6 Every weekday patient attends day-care in the morning with pulse, temperature and BP being done on arrival before receiving clozapine dose and before going home. Although patient may be allowed to leave the unit during the day, they should return for their final pulse, temperature and BP readings 6 hours after the dose of clozapine was given. Patient is given weekend supply of medication on Fridays. 5.7 There should be somewhere for patient to sit or lie quietly should they need to. 5.8 Utilise a flexible dosage titration some patients may require slow dosage titration. 5.9 Do not increase the dose of clozapine at the weekend or on bank holidays Clozapine dose may be divided after one week depending on preference for type of dosing regimen and adverse reactions experienced. Version 1.0 January

8 5.11 A doctor should see the patient regularly and at a minimum once every week. The doctor should assess the patient in a similar way to that which would be carried out if the patient was an in-patient, i.e. assessing the patient s progress, assessing any adverse reactions to clozapine, adjusting the titration rate, managing anti-psychotic medication cross-titration, reassuring the patient. 6. Documentation and support tools 6.1 Patient s case notes should be used to document the giving of information to patients and their families and the patient s consent. The out patient initiation checklist (appendix 1) should be completed, signed by the patient and a copy given to the patient. 6.2 Results from investigations should be filed in the patient s notes. A temperature, pulse and blood pressure chart should be used throughout the period of initiation and filed in the patient s notes. 6.3 Records should be detailed in the case notes of patient s experience and formal assessment of side effects. 6.4 Any adverse event should be reported to the ZTAS as well as to the R.M.O and appropriate action should be taken that may include reducing/ stopping clozapine,hospitalization etc. 7. Training & Audit This service will be audited for the numbers referred, started on clozapine, successful completion as well as adverse events. There is sufficient experience within the team to be able to initiate clozapine and a refresher course will be arranged for those needing to update their skills and knowledge. 8. Abbreviations. BP: Blood pressure. ZTAS: Zaponex Treatment Access system. Version 1.0 January

9 R.M.O: Responsible Medical Officer. G.P: General Practitioner. CR/HT Crisis Resolution/Home Treatment team. MAOI: Monoamine oxidase inhibitors. CNS: Central Nervous system ECG: Electro cardiogram NMS: Neuroleptic Malignant Syndrome. Version 1.0 January

10 Clozapine Out-Patient Initiation Checklist Initiation of Clozapine Treatment for Patients in the Community Appendix 1 Start Date (Day 1, Monday): Patient name: Patient date of birth: Patient s address: Consultant: Key worker: Patient s emergency contact tel. no: Setting: Ward Day care Home / hostel Current medication name Current dose Before giving clozapine: Patient considered suitable for out-patient care Patient given clozapine information including expected time frame for recovery Family/carer given clozapine information including expected time frame for recovery Patient aware of necessity for daily attendance / home visits Person available to accompany patient home (if applicable) Family / carer available to stay overnight Patient given information on recognition of side effects & what to do if they occur Family/carer given info. on recognition of side effects & what to do if they occur Patient has given their consent for clozapine treatment and blood tests Recent full history taken & recorded Recent clinical examination performed & recorded Completed ZTAS Registration form sent to Pharmacy First blood taken (local). Green blood test result required. GP informed of start date; provided with guidelines & emergency contact number(s) Emergency contact number provided to patient Medication Collected from Pharmacy Signature of care co-ordinator/ nominated team member:... Signature of Patient: Copy Given to Patient / Carer Version 1.0 January

11 Appendix 2 Clozapine Initiation Prescription Chart Patients Name: Age: Consultant: Notes: This prescription chart is only used for prescribing and recording the administration of clozapine during initiation of treatment. Please refer to the main prescription chart for any other medication. The responsible medical officer should sign the chart at the start of each week and insert the appropriate date in each of the boxes provided. The nurse administering the clozapine should sign in the box beside the relevant dose. Please consult the guidance notes for further information. WEEK No. 1. Signature of Medical officer: Day Total daily dose Date Morning Dose Given by Evening Dose Given by mg Clozapine 12.5mg None 2 25mg Clozapine 12.5mg Clozapine 12.5mg mg Clozapine 12.5mg Clozapine 25mg 4 50mg Clozapine 25mg Clozapine 25mg 5 75mg Clozapine 25mg Clozapine 50mg 6 100mg Clozapine 25mg Clozapine 75mg 7 100mg Clozapine 25mg Clozapine 75mg WEEK No. 2 Signature of Medical Officer: 8 125mg Clozapine 50mg Clozapine 75mg 9 150mg Clozapine 50mg Clozapine 100mg mg Clozapine 50mg Clozapine 100mg mg Clozapine 50mg Clozapine 125mg mg Clozapine 100mg Clozapine100mg mg Clozapine 100mg Clozapine 125mg mg Clozapine 100mg Clozapine 150mg Version 1.0 January

12 Patients Name: Age: Consultant: If it is not intended to continue dose titration to 400mg, then the boxes not required should be crossed out. When the required dose is reached, this chart should be crossed out and initialled by the medical officer. The final dose should be written up in the normal inpatient prescription chart. WEEK No.3 Signature of Medical officer: Day Total Daily Dose Date Morning Dose Given by Evening Dose Given by mg Clozapine 100mg Clozapine 175mg mg Clozapine 100mg Clozapine 200mg mg Clozapine 100mg Clozapine 200mg mg Clozapine 100mg Clozapine 200mg mg Clozapine 100mg Clozapine 200mg mg Clozapine 100mg Clozapine 200mg mg Clozapine 100mg Clozapine 250mg WEEK No. 4 Signature of Medical officer: mg Clozapine 100mg Clozapine 250mg mg Clozapine 100mg Clozapine 250mg mg Clozapine 100mg Clozapine 300mg mg Clozapine 100mg Clozapine 300mg mg Clozapine 100mg Clozapine 300mg mg Clozapine 100mg Clozapine 300mg mg Clozapine 100mg Clozapine 300mg Version 1.0 January

13 Appendix 3 Example Community Initiation of Clozapine sliding dosage schedule. Titration and use of other antipsychotics Day Clozapine dose (daily) Comments mg 2 25mg mg 4 50mg 5 75mg 6,7 (weekend) 75mg Do not increase over weekend 8 100mg 9 125mg thereafter Increase by 25mg every 2 days Increase to 300mg daily, then review The dose should be increased more gradually if side effects appear. Version 1.0 January

14 Policy Details Title of Policy Unique Identifier for this policy State if policy is New or Revised Initiation of Clozapine Treatment Community Patients New Previous Policy Title where applicable Policy Category Clinical, HR, H&S, Infection Control etc. Executive Director whose portfolio this policy comes under Policy Lead/Author Job titles only Committee/Group responsible for the approval of this policy Month/year consultation process completed * n/a Medicines Management Medical Director Month/year policy approved January 2015 Month/year policy ratified and issued January 2015 Next review date February 2016 Consultant for Crisis Resolution & Home Treatment Medicines Management Committee Implementation Plan completed * Equality Impact Assessment completed * Previous version(s) archived * Disclosure status Yes Yes Yes B can be disclosed to patients and the public Key Words for this policy * For more information on the consultation process, implementation plan, equality impact assessment, or archiving arrangements, please contact Corporate Governance Review and Amendment History Version Date 1.0 January 2015 Details of Change Reformatted to meet new Trust policy template Version 1.0 January

Integrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION

Integrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION Document Reference MM 049 Integrated Care Pathway (ICP) for the Management of clozapine COMMUNITY INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant

More information

Policy & Procedures Committee Date: 18 January 2018

Policy & Procedures Committee Date: 18 January 2018 Clinical SOP Out-patient Clozapine Initiation Procedure SOP Document Control Summary Status: Replacement supersedes Clozapine Policies and Procedures Version: v1.0 Date: October 2017 Hayley Smart Mo Azar

More information

Clozapine Outpatient initiation

Clozapine Outpatient initiation Clozapine Outpatient initiation 1. Introduction The licence for clozapine enables commencement of clozapine as an outpatient. Hospital admission for initiating clozapine has been recommended in the past

More information

Integrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION

Integrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant

More information

Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT

Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Version: 1 Author: Ambreena Asghar Designation: Pharmacist Responsible Director: Sharon Binyon Approved By: Drugs and Therapeutics

More information

Claire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No.

Claire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No. Pharmacological Therapy Policy Practice Guidance Note Safe Prescribing of Clozapine V02 Version issued Issue 1 Jan 16 Issue 2 Nov 16 Planned review January 2019 PPT-PGN-05 Part of NTW(C)38 Pharmacological

More information

STARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.

STARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management

More information

Datix Ref:

Datix Ref: Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document

More information

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact

More information

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines

More information

North Central London Medicines Optimisation Committee

North Central London Medicines Optimisation Committee North Central London Medicines Optimisation Committee Guidance for Pharmacy Staff Managing Clozapine For Patients Admitted to Acute Hospitals Disclaimer This guideline is registered at North Central London

More information

Clozapine intramuscular (IM) Guideline, inpatients only

Clozapine intramuscular (IM) Guideline, inpatients only SH CP 203 Clozapine intramuscular (IM) Guideline, inpatients only Summary: Guideline for use and monitoring of intramuscular clozapine treatment. Keywords: Target Audience: Clozapine, intramuscular, IM,

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and

More information

PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE

PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,

More information

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines \ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents

More information

Clozapine Service Standards

Clozapine Service Standards Clozapine Service Standards Policy Number: MHP SUM Oct 2013 Implementation Date: Nov 2013 First Review Date: Nov 2015 Review Frequency: Bi-Annual The MHS Clozapine Review Group is responsible for monitoring

More information

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical

More information

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting

Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation

More information

Policy for the safe use of oral methotrexate

Policy for the safe use of oral methotrexate Policy for the safe use of oral methotrexate Policy Checklist Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Does this meet criteria of a Policy? Staff side

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

Standard Operating Procedure: Early Intervention in Psychosis Access Times

Standard Operating Procedure: Early Intervention in Psychosis Access Times Corporate Standard Operating Procedure: Early Intervention in Psychosis Access Times Document Control Summary Status: New Version: V1.0 Date: Author/Owner: Rob Abell, Senior Performance Development Manager

More information

HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT)

HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) Document Reference Version Number 2.00 High Dose Antipsychotic Guidelines (HDAT) G376 Author/Lead Job Title Jackie Stark Principal Pharmacist Clinical Services

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file

More information

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off Policy For The Adjustment Of Insulin Injections By Paediatric Diabetes Specialist Nurses/Community Paediatric Nurses Diabetes Working With Children Within NHS Grampian Co-ordinators: Lead Paediatric Diabetes

More information

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016 POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing

More information

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated

More information

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02. Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder

More information

Assessment of Mental Capacity and Best Interest Decisions

Assessment of Mental Capacity and Best Interest Decisions Standard Operating Procedure 1 (SOP 1) Assessment of Mental Capacity and Best Interest Decisions Why we have a procedure? This Standard Operating Procedure (SOP) is required to set out how a person s capacity

More information

02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST

02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST Service Specification No. Service Commissioner Leads 02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical Provider Lead POOLE HOSPITAL NHS FOUNDATION TRUST Period 1 April 2013 to 31

More information

Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy

Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas

More information

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Virginia. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Interprofessional Primary Care Medical Directive for Smoking Cessation

Interprofessional Primary Care Medical Directive for Smoking Cessation Insert Logo or Org Name Here Interprofessional Primary Care Medical Directive for Smoking Cessation Adapted from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 14,

More information

Pathology Service User Guide Haematology

Pathology Service User Guide Haematology Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin

More information

Introduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients)

Introduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients) Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients) Introduction This guideline is designed to provide a framework for patients to administer

More information

CLOZAPINE TREATMENT GUIDELINES MARCH 2017

CLOZAPINE TREATMENT GUIDELINES MARCH 2017 CLOZAPINE TREATMENT GUIDELINES MARCH 2017 0 Policy title Clozapine treatment guidelines Policy PHA06 reference Policy category All clinical staff who deal with medication in the Trust. Relevant to Clinical

More information

Trust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU)

Trust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU) A Protocol For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name and job title of document author s Line Manager: Supported by:

More information

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of

More information

Thrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers

Thrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers Thrombosis and Anticoagulation Team Warfarin Information for patients, relatives and carers What is warfarin? Warfarin is an anticoagulant. Anticoagulants are drugs which prevent harmful blood clots forming

More information

A new model for prescribing varenicline

A new model for prescribing varenicline Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand

More information

The licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.

The licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia. 1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,

More information

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011 POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1

More information

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Ongoing care for adults with psychosis or schizophrenia bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly

More information

A three month project September December 2016

A three month project September December 2016 Improving Insulin Safety in the Clinical Decision Unit A three month project September December 2016 Sarah Gregory - In-Patient DSN, QEQM Hospital Julie Gammon - Ward Manager, CDU, QEQM Hospital 1 The

More information

GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS. Version 5 December 2017

GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS. Version 5 December 2017 GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP

More information

28 th September Author Jeremy Gilbert Bariatric Nurse Specialist

28 th September Author Jeremy Gilbert Bariatric Nurse Specialist POLICY FOR SELF ADMINISTRATION OF CONTINUOUS POSITIVE AIRWAY PRESSURE BY COMPETENT PATIENTS COMING IN FOR METABOLIC AND OBESITY SURGERY (BARIATRIC SURGERY) TO PENDENNIS WARD 28 th September 2014 Author

More information

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

NO SMOKING POLICY. Organisational

NO SMOKING POLICY. Organisational NO SMOKING POLICY Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For clinical policies only - state index

More information

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities

More information

Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services

Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services NHS GGC Mental Health Service Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services Important Note: The Intranet version of this document

More information

Guidance for Pharmacists on Safe Supply of Oral Methotrexate

Guidance for Pharmacists on Safe Supply of Oral Methotrexate Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2

More information

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

patient group direction

patient group direction DIAZEPAM v01 1/9 DIAZEPAM PGD Details Version 1.0 Legal category Staff grades Approved by CD Benz POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Management Guidance HR72 On-Call Policy. The Trust s Approach to Compensatory Rest

Management Guidance HR72 On-Call Policy. The Trust s Approach to Compensatory Rest Management Guidance HR72 On-Call Policy The Trust s Approach to Compensatory Rest General Principles Compensatory rest may be granted if either: An individual s daily or weekly rest requirements (as stated

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

NRT Voucher redemption scheme service specification

NRT Voucher redemption scheme service specification NRT Voucher redemption scheme service specification Updated March 2016 Review date March 2018 Page 1 of 7 1. Introduction The NRT voucher scheme is for NHS Fife stop smoking advisors who have been deemed

More information

Clozapine Shared Care Protocol And Information For Oxfordshire GPs

Clozapine Shared Care Protocol And Information For Oxfordshire GPs Clozapine Shared Care Protocol And Information For Oxfordshire GPs There should be willing consent of all parties to enter into a shared care agreement. This includes patients (plus carers if necessary)

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to

More information

Smoking Cessation Pharmacotherapy Guidelines

Smoking Cessation Pharmacotherapy Guidelines Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence

More information

CP80 Version: V01. Acute Oncology Management Service Date approved: 8 th May 2015 Date ratified: 1 st June 2015 Review date: 1 st June 2017

CP80 Version: V01. Acute Oncology Management Service Date approved: 8 th May 2015 Date ratified: 1 st June 2015 Review date: 1 st June 2017 STANDARD OPERATING PROCEDURE (SOP) AND PATHWAY FOR THE MANAGEMENT OF PATIENTS WITH METASTATIC SPINAL CORD COMPRESSION (MSCC) WITHIN THE CHRISTIE (Refer to the Manchester Cancer Network MSCC Pathway flowchart)

More information

INFORMATION SHEET FOR THE DEPARTMENT OF PAIN AND PALLIATIVE CARE

INFORMATION SHEET FOR THE DEPARTMENT OF PAIN AND PALLIATIVE CARE INFORMATION SHEET FOR THE DEPARTMENT OF PAIN AND PALLIATIVE CARE Please review the following instructions as it contains important information regarding the management of your pain. Once reviewed, our

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute

More information

Policy Register No: Status: Public. Contributes to Care Quality Commission Outcome 4

Policy Register No: Status: Public. Contributes to Care Quality Commission Outcome 4 Operational Policy for Transfer of ST Elevation MI (STEMI) patients to Essex Cardiothoracic Centre (ECTC) for Primary Percutaneous Coronary Intervention Policy Register No: 09122 Status: Public Developed

More information

SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline

SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

Novel oral anticoagulant therapy (NOAC)

Novel oral anticoagulant therapy (NOAC) Haematology Department Novel oral anticoagulant therapy (NOAC) Information for patients, relatives and carers What is novel oral anticoagulant therapy? Novel oral anticoagulants, or NOACs, are drugs which

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

2010 National Audit of Dementia (Care in General Hospitals) North West London Hospitals NHS Trust

2010 National Audit of Dementia (Care in General Hospitals) North West London Hospitals NHS Trust Royal College of Psychiatrists 2010 National Audit of Dementia (Care in General Hospitals) Organisational checklist results and commentary for: rth West London Hospitals NHS Trust The 2010 national audit

More information

Locally Enhanced Service for Stopping Smoking

Locally Enhanced Service for Stopping Smoking NHS Devon Locally Enhanced Service for Stopping Smoking This Local Enhanced Service (LES) Specification details the agreement between Devon PCT (the commissioner) and community pharmacies (the service

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,

More information

North East Essex Medicines Management Committee

North East Essex Medicines Management Committee Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES

More information

Management of Preschool Aged Children Paediatric Physiotherapy Service (Excluding Neonatal)

Management of Preschool Aged Children Paediatric Physiotherapy Service (Excluding Neonatal) Standard Operating Procedure 2 (SOP 2) Paediatric Physiotherapy Service (Excluding Neonatal) Why we have a procedure? To ensure the timely and equitable management of preschool aged children through the

More information

Alcohol Opiates Other:

Alcohol Opiates Other: Pages 1 and 2 must be completed in full for all referrals (incomplete forms will not be processed) Additional Required Information Form must be completed for all referrals Medication Clinic (Pg. 3), ECT

More information

1. Intrathecal must never be abbreviated to IT on a prescription form True / False

1. Intrathecal must never be abbreviated to IT on a prescription form True / False Appendix 1: Intrathecal SACT Assessment Questions Core General Questions must be completed by all staff. 1. Intrathecal must never be abbreviated to IT on a prescription form 2. Intrathecal SACT must be

More information

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS Date 20 th November 2014 Our Ref HDAT_MGPG/Nov14 Enquiries to Caroline Hind Extension 56088 Direct Line 01224 556088 Email caroline.hind2@nhs.net

More information

patient group direction

patient group direction SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510

COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510 COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510 Effective Date: August 31, 2006 SUBJECT: CARE OF THE INDIVIDUAL RECEIVING CLOZAPINE 1. GENERAL: Clozapine

More information

PATIENT GROUP DIRECTION PROCEDURE

PATIENT GROUP DIRECTION PROCEDURE PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen

More information

Trust Policy 218 Ionising Radiation Safety Policy

Trust Policy 218 Ionising Radiation Safety Policy Trust Policy 218 Ionising Radiation Safety Policy Purpose Date Version August 2016 7 To ensure that Plymouth Hospitals NHS Trust complies with all relevant legislation with regard to the use of ionising

More information

GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018)

GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018) GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS Version 1 (reviewed unchanged January 2018) RATIFYING COMMITTEE Drugs and Therapeutics Group DATE ORIGINALLY 29 th October2014

More information

Updated: 08/2017 DMMA Approved: 11/2017

Updated: 08/2017 DMMA Approved: 11/2017 Request for Prior Authorization for Therapy to Treat Binge Eating Disorder Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for medications to treat Binge

More information

Having a diagnostic catheter angiogram

Having a diagnostic catheter angiogram Having a diagnostic catheter angiogram This information leaflet will explain what an angiogram is and why you have been sent for one. Please read this leaflet carefully. If you have any questions or concerns

More information

Ref : 06:01:PP:019: NIBT Issue Date: September 2006 Page: 1 of 8 NORTHERN IRELAND BLOOD TRANSFUSION SERVICE ALCOHOL & DRUGS POLICY AND PROCEDURE

Ref : 06:01:PP:019: NIBT Issue Date: September 2006 Page: 1 of 8 NORTHERN IRELAND BLOOD TRANSFUSION SERVICE ALCOHOL & DRUGS POLICY AND PROCEDURE Ref : 06:01:PP:019: NIBT Issue Date: September 2006 Page: 1 of 8 NORTHERN IRELAND BLOOD TRANSFUSION SERVICE ALCOHOL & DRUGS POLICY AND PROCEDURE 1 Introduction The Northern Ireland Blood Transfusion Service

More information

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 4 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Authors details Michael Slater (Clinical Pharmacist, tel. 01625

More information

Chemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers

Chemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

GENERAL PRACTITIONER (GP) SUPPORT PACK

GENERAL PRACTITIONER (GP) SUPPORT PACK Document Reference MM 050 Integrated Care Pathway (ICP) for the Management of clozapine GENERAL PRACTITIONER (GP) SUPPORT PACK One pack to be printed for each patient initiated on clozapine treatment,

More information

Clozapine Prescribing and Monitoring Guideline

Clozapine Prescribing and Monitoring Guideline Document level: Trustwide (TW) Code: MP5 Issue number:6 Clozapine Prescribing and Monitoring Guideline Lead executive Authors details Type of document Target audience Document purpose Dr A Sivananthan

More information

ESSENTIAL SHARED CAR E AGREEMENT FOR

ESSENTIAL SHARED CAR E AGREEMENT FOR E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some

More information

2010 National Audit of Dementia (Care in General Hospitals) Chelsea and Westminster Hospital NHS Foundation Trust

2010 National Audit of Dementia (Care in General Hospitals) Chelsea and Westminster Hospital NHS Foundation Trust Royal College of Psychiatrists 2010 National Audit of Dementia (Care in General Hospitals) Organisational checklist results and commentary for: NHS Foundation Trust The 2010 national audit of dementia

More information